Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors
May 25, 2021 09:00 ET | Source: Longeveron Longeveron Miami, Florida, UNITED STATES
MIAMI, May 25, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Ursula Ungaro will be joining its Board of Directors as of June 1, 2021.
Ms. Ungaro was appointed to serve on the federal U.S. District Court for the Southern District of Florida in 1992 after being nominated by President George H.W. Bush and being confirmed by the U.S. Senate. After 29 years of federal service, Ms. Ungaro has announced that she will be retiring from the bench on May 31, 2021. In her time on the federal bench, she presided over and ruled in numerous major civil and criminal cases in legal domains ranging
Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations Agreement Provides Additional Intellectual Property and Clinical Data for Longeveron While Strengthening Research and Development Relationship
March 10, 2021 08:30 ET | Source: Longeveron Longeveron Miami, Florida, UNITED STATES
MIAMI, March 10, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the Company has expanded and amended its exclusive license agreement (ELA) related to Lomecel-B technology rights, and entered into a Collaborative Research and Development Agreement (CRADA) with the University of Miami (UM).
Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors
February 18, 2021 08:30 ET | Source: Longeveron Longeveron
MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE)
Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Company’s Board of Directors.
Douglas Losordo, MD
Dr. Losordo has worked in the biotech industry for over twenty years, most recently serving as Executive Vice President, Head of Research and Development and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage bioph